fashion -WSS

fashion

author：focus 2025-09-06 03:55:39 - browse：62943

Andrew Trister, an oncologist and veteran of big technology companies and research, is Verily's new chief scientific officer.

As Verily aims to get on track, the Alphabet life science company has hired Andrew Trister, an oncologist and veteran of big technology companies and research, as its new chief scientific officer.

Trister will lead Verily’s population health initiatives, including public health solutions like the company’s ongoing work to combat disease-carrying mosquito populations and a program that helps wastewater treatment plants monitor for pathogens. He will also consult across Verily’s diverse projects.

Trister’s focus on public health will build on his recent role as a deputy director at the Bill and Melinda Gates Foundation, where he led digital health, including a project to build tech infrastructure to help with malaria testing. Trister also led the foundation’s Covid-19 response. In 2016, he was an early health hire at Apple. There, he worked on programs like a heart health study with Janssen, an app to promote healthy habits with Aetna, and research into digital biomarkers for Alzheimer’s disease with Eli Lilly and Evidation.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Medicare drug price negotiation hearing pits pharma v Biden admin

WSS

Medtronic CEO on promising devices for diabetes, hypertension

An exit interview with Bristol Myers Squibb CEO Giovanni Caforio

Pregnant women don't need prenatal multivitamins, study concludes

Longer MASH drug regimen improved liver, Akero study finds

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Chimpanzees, like humans and whales, get menopause: Study

Wikipedia

fashion

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

He's 19 months old and has one of the world’s rarest diseases

After affirmative action ruling, medical educators look to 'holistic review'

The FDA weighs the risks of candy

BioMarin wins approval for gene therapy to treat hemophilia A

Harvard's David Sinclair gets blowback over aging

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout Newsletter: What happened with Sarepta's Duchenne data

Dobbs anniversary: the lost opportunity of abortion as health care

STAT Wunderkinds: Ruey Hu's digital tools for parsing research

explore

Traditional Chinese medicine benefits explored in new JAMA study

Why Talkspace is targeting Medicare, a tricky market

Longer MASH drug regimen improved liver, Akero study finds

Chimpanzees, like humans and whales, get menopause: Study

WHO may add ‘noma' to its list of neglected tropical diseases

Telehealth options flood the market as retailers push virtual care

focus

focus

focus

hotspot